Gambaran corticophobia pada pasien psoriasis Indonesia: Studi berbasis TOPICOP
DOI:
https://doi.org/10.25170/djm.v23i3.5639Keywords:
Corticophobia, Kortikosteroid topikal, TOPICOPAbstract
Pendahuluan: Corticophobia adalah kekakutan atau kekhawatiran terhadap kortikosteroid topikal (topical corticosteroids, TCS), terutama terhadap efek sampingnya, seperti penipisan kulit. Dampak yang paling dikhawatirkan dengan corticophobia adalah ketidakpatuhan terhadap pengobatan TCS. Penelitian ini bertujuan untuk mencari gambaran corticophobia di Indonesia yang belum pernah dilakukan sebelumnya.
Metode: Sebuah kuesioner disebar pada story Instagram pada akun Instagram dari organisasi Psoriasis Indonesia @psoriasis_id. Kuesionernya berisi identitas pasien, diagnosis kualitatif corticophobia, riwayat penggunaan TCS, dan kuesioner TOPICOP yang telah diterjemahkan ke bahasa Indonesia. Kriteria inklusi adalah pasien atau orang tua pasien psoriasis.
Hasil: Sebanyak 204 responden yang telah memenuhi kriteria inklusi diminta untuk mengisi kuesioner. Prevalensi corticophobia adalah 76% dengan nilai rerata TOPICOP 68,3%, keduanya relatif tinggi dibanding negara lainnya. Domain dengan nilai TOPICOP tertinggi adalah domain kekhawatiran, sedangkan item dengan nilai TOPICOP tertinggi adalah “Saya memerlukan kepastian keamanan penggunaan TCS.” Pada penelitian ini, perempuan juga secara konsisten memiliki prevalensi corticophobia dan nilai TOPICOP lebih tinggi pada setiap populasi.
Simpulan: Intervensi yang sesuai terdiri dari edukasi yang tepat dan menjaga hubungan dokter-pasien harus dilakukan pada pasien dengan atau berisiko mengalami corticophobia, dan penelitian corticophobia di Indonesia yang lebih luas dengan jumlah sampel lebih besar dan pada populasi lain masih dibutuhkan.
Kata Kunci: corticophobia, kortikosteroid topikal, TOPICOP
Downloads
References
Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in atopic dermatitis: A systematic review. JAMA Dermatol. 2017 Oct 1;153(10):1036-42.
Gidaris DK, Stabouli S, Bush A. Beware the inhaled steroids or corticophobia? Swiss Med Wkly. 2021 Feb 6;151:w20450.
Müller SM, Tomaschett D, Euler S, Vogt DR, Herzog L, Itin P. Topical corticosteroid concerns in dermatological outpatients: A cross-sectional and interventional study. Dermatology. 2016;232(4): 444-52.
Ahmad DS, Wazaify MM, Albsoul-Younes A. The role of the clinical pharmacist in the identification and management of corticophobia - An interventional study. Tropical Journal of Pharmaceutical Research. 2014;13(3):445–53.
Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019 Apr 1;80(4):1029–72.
Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D,
Ferreira J, Filipe P. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012; 2012:561018.
Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000 May;142(5):931-6.
Mueller SM, Itin P, Vogt DR, Walter M, Lang U, Griffin LL, Euler S. Assessment of "corticophobia" as an indicator of non-adherence to topical corticosteroids: A pilot study. J Dermatolog Treat. 2017 Mar;28(2):104-11.
Herzum A, Occella C, Gariazzo L, Pastorino C, Viglizzo G. Corticophobia among parents of children with atopic dermatitis: assessing major and minor risk factors for high TOPICOP scores. J Clin Med. 2023 Oct 27;12(21):6813.
Alharbi AA, Alhetheli GI, Alqahtani R, Alshehri M. The effects of topical steroid fears and concerns on patients with eczema: first TOPICOP© scale-based study in Saudi Arabia. International Journal of Research in Dermatology. 2021 Feb 22;7(2):155.
Huynh RK, Wong HH, Aw DCW, Toh MPHS. Adherence to topical corticosteroids and moisturisers in adults with endogenous eczema in Singa-pore. Hong Kong J Dermatol Venereol. 2015;23: 161–74.
Gomes TF, Kieselova K, Guiote V, Henrique M, Santiago F. A low level of health literacy is a predictor of corticophobia in atopic dermatitis. An Bras Dermatol. 2022 Nov 1;97(6):704–9.
Lee JY, Her Y, Kim CW, Kim SS. Topical corticosteroid phobia among parents of children with atopic eczema in Korea. Ann Dermatol. 2015 Oct 1;27(5):499–506.
Song SY, Jung SY, Kim E. Steroid phobia among general users of topical steroids: a cross-sectional nationwide survey. J Dermatolog Treat. 2019 May;30(3):245-50.
Lambrechts L, Gilissen L, Morren MA. Topical corticosteroid phobia among healthcare professionals using the TOPICOP score. Acta Derm Venereol. 2019 Oct 1;99(11):1004–8.
Smith SD, Hong E, Fearns S, Blaszczynski A, Fischer G. Corticosteroid phobia and other confounders in the treatment of childhood atopic dermatitis explored using parent focus groups. Australas J Dermatol. 2010 Aug;51(3):168-74.
Tan S, Phan P, Law JY, Choi E, Chandran NS. Qualitative analysis of topical corticosteroid concerns, topical steroid addiction and withdrawal in dermatological patients. BMJ Open. 2022 Mar 16;12(3).
Aubert-Wastiaux H, Moret L, Le Rhun A, Fontenoy AM, Nguyen JM, Leux C, et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins, and frequency. Br J Dermatol. 2011 Oct;165(4):808-14.
Kojima R, Fujiwara T, Matsuda A, Narita M, Matsubara O, Nonoyama S, et al. Factors associated with steroid phobia in caregivers of children with atopic dermatitis. Pediatr Dermatol. 2013 Jan;30(1):29–35.
Alinia H, Moradi Tuchayi S, Smith JA, Richardson IM, Bahrami N, Jaros SC, et al. Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring. Br J Dermatol. 2017 Mar;176(3):759-64.
Alsubeeh NA, Alsharafi AA, Ahamed SS, Alajlan A. Treatment adherence among patients with five dermatological diseases and four treatment types - a cross-sectional study. Patient Prefer Adherence. 2019 Dec 3;13:2029-38.
Stalder JF, Aubert H, Anthoine E, Futamura M, Marcoux D, Morren MA, et al. Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the TOPICOP score. Allergy. 2017 Nov;72(11):1713-9.
Choi E, Chandran NS, Tan C. Corticosteroid phobia: A questionnaire study using TOPICOP score. Singapore Med J. 2020 Mar 1;61(3):149–53.
Moret L, Anthoine E, Aubert-Wastiaux H, Le Rhun A, Leux C, Mazereeuw-Hautier J, et al. TOPICOP©: a new scale evaluating topical corticosteroid phobia among atopic dermatitis outpatients and their parents. PLoS One. 2013 Oct 16;8(10):e76493.
Moawad S, Mahé E, Aubert-Wastiaux H, Phan A, Maruani A, Chiaverini C, et al. Topical corticosteroid concerns among parents of children with psoriasis versus atopic dermatitis: A French multi-center cross-sectional study. Am J Clin Dermatol. 2018 Apr 1;19(2):261–5.
Contento M, Cline A, Russo M. Steroid phobia: A review of prevalence, risk factors, and interventions. Am J Clin Dermatol. 2021 Nov;22(6):837-51.
Millard AN, Stratman EJ. Assessment of topical corticosteroid prescribing, counseling, and communication among dermatologists and pharmacists.
JAMA Dermatol. 2019 Jul 1;155(7):838–43.
Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016 Nov 17;10:2357-67.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Damianus Journal of Medicine
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
